Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

NCT06763965 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ENROLLING_BY_INVITATION

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent High-grade Glioma

Interventions

BIOLOGICAL: BioTTT001 injection

Sponsor

Beijing Bio-Targeting Therapeutics Technology Co., Ltd